moderater dry eye - ois · §dry eye disease is a very common disorder that is often ignored and...
TRANSCRIPT
Dry Eye Breakout Session
ModeraterEdward Holland, MD, Director, Cornea Service - Cincinnati Eye Institute/ Professor of Clinical Ophthalmology - University of Cincinnati
Panel Kim Brazzell, MD, PhD, Chief Medical Officer - Kala Pharmaceuticals
Preeya Gupta, MD, Associate Professor, Ophthalmology - Duke Eye Center
Patrick Mooney, VP & Head, Ophthalmology Franchise – Novartis
Elizabeth Yeu, MD, Partner - Virginia Eye Consultants / Assistant Professor, Ophthalmology - Eastern Virginia Medical School
Dry Eye Disease Market Overview
.
Financial Disclosures
• Aerie• Allegra• Alcon Laboratories, Inc.• Azura• BlephEx• BrimBiotech• CorneaGen• Dompe• EyePoint• Inversa• Johnson and Johnson• Kala Pharmaceuticals• Mati Pharmaceuticals• Merk KGgA• Novartis• Omeros• Ocuphire• Oyster Point• PreciseBio• ReTear• Senju • SightScience• SilkTech• Stuart• Takeda• TearLab• TopiVert• Vomaris• Zeiss
344 MILLION
WORLDWIDE
15-20MILLION
IN THE US
Market Scope estimates, Market Scope Dry Eye Report, 2016
Up to 30 -40 Million Undiagnosed in the US
INCREASINGLYPREVALENT RISK FACTORS
CONTACT LENS USE• 1 in 6 US adults wears contact lenses.1
• 73% of contact lens users report dissatisfaction or discontinuation due to symptoms.2
MULTISCREEN LIFESTYLE• 6 in 10 adults spend 5 or more hours/day on digital
devices3
• 1 in 4 kids spend 3 hours/day using digital devices3
• 92% of ECPs suspect modern technology contributes to dry eye symptoms4
OCULAR SURGERY• 48% of post-LASIK patients reported dryness for 6
months5
• Increased risk in post- cataract patients
1. Cope JR et al. Centers for Disease Control and Prevention. 2015;64(32):865-870. 2. Richdale K et al. Cornea. 2007;26(2):168-174. 3. Vision Council. 2015 Digital Eye Strain Report. 4. Shire National Eye C.A.R.E. Survey. 2016. 5. Market Scope estimates, Market Scope Dry Eye Report, 2016.
DOMINANT RISK FACTOR:
GROWTH OF AT-
RISK
POPULATION
The major factor determining
increase in dry eye prevalence over
the next 20 years is the size of
population at risk for dry eye.1
10,000 baby boomers will turn 65 years old every day until 2030.2
By 2050, 21% of the overall population will be over 65.2
1. Dry Eye Epidemiology. Decision Resources Group. December 2015. 2. Pew Research Center. Baby Boomers Retire. Dec 29, 2010. Available at: http://www.pewresearch.org/fact-tank/2010/12/29/baby-boomers-retire/. Accessed on April 4, 2017.
13.6 MILLION TREATED WITH ARTIFICIAL
TEARS OR Rx
6 MILLION REMAIN UNTREATED
Market Scope estimates, Market Scope Dry Eye Report, 2016
IN THE US...
GLOBAL DRY EYE POPULATION: TREATED vsUNTREADED
0
20
40
60
80
US WesternEurope
Japan OWN China India LatinAmerica
MIL
LIO
NS A
FFEC
TED
BY D
RY E
YE
Treated Untreated OWN = Other Wealthy Nations
Market Scope estimates, Market Scope Dry Eye Report, 2016.
F
16.4%11.5%
7.7%
3.0%
0.7%
0.7%1.5%
58.6%
Global Dry Eye Market Revenues
United States
Western Europe
Japan
OWN
China
Latin America
India
ROW
0%
5%
10%
15%
20%
25%
United States
Weste
rn Euro
peJapan
OWN
ChinaIndia
Latin
America
ROWGlobal
3.1%
8.1%
2.8%
6.1%
21.4%
25.1%
15.3%
19.1%
5.5%
Forecast for Compounded Growth in the Global Dry Eye Market
OWN = Other Wealthy Nations
ROW = Rest of World
DRY EYE - HEALTHY MARKET US AND GLOBAL MARKET POSITIONED FOR GROWTH
Market Scope estimates, Market Scope Dry Eye Report. R
eve
nu
e C
AG
R:
20
16
-20
21
DRY EYE Landscape 201714 PRODUCTS IN CLINICAL DEVELOPMENT
TrueTear
Klarity
Discovery
2017
Lau
nche
s
Phas
e 3
Phas
e1/
2
CyclASol
Restasis X
P-321
ISV-101
Lubricin; VAY736
Dextenza
Seciera
KPI-121
RGN-259
MIM-D3
SkQ1
Dry eye landscape 2019
Pre-clinical Phase 1 Phase 2 Phase 3 Pre-Reg Approved
Infla
mm
ator
yNo
n-in
flam
mat
ory
KPI-121
Cequa
CyclASol
T-1580
OCU-310
TOP1630
PADcicloVoclosporin
ADX-102
HL036
OC-01, OC-02
rhDNase
Elate Ocular
NM133
SDP-4Nov-07
SURF-100
Restasis
HU-007
Ikervis, Diquas Klarity-C
Softacort / Softacor1
CsA- MiDROPS
PP-001
KPI-190
Pro-OcularSA001, SJP002
HU-024
ZK-014
NOV033
OKYO-0101
Xiidra
1Softacort is only approved for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases; however, a Phase 4 trial has recently been initiated investigating efficacy in patients with chronic DED and ocular surface inflammation
Tear Lab Discovery
Diagnostic device
2The lead indication for Oxervate is neurotrophic keratitis (NK) and this is the only indication for which the asset has received regulatory approval in Europe and the US3Approved in the EU as the OTC product EvoTears
Ocular NaV1.7
Unnamedprogram
OCU-001
SI-01
BRM-421
Oxervate2
AVX-012
TAK759
ECF-843
Lacripep
OCS-02
RP101
Visomitin
RGN-259
SYL-1001
SJP-0035
YY-101
Palovarotene
VVN001
Treatment Strategies for Meibomian Gland Dise
ase
Conclusion
§ Dry eye disease is a very common disorder that is often ignored and underdiagnosed by clinicians
§ Dry eye disease can have a significant impact on:• Patients’ vision, comfort, and
quality of life• Your surgical outcomes
§ Dry eye disease is progressive § New technologies will improve
the clinicians’ ability to properly and efficiently diagnose dry eye
§ New treatments will provide more effective options for treatment of dry eye disease